학술논문

Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+NSCLC (POPLAR and OAK)
Document Type
Journal
Source
ANNALS OF ONCOLOGY; SEP 2017, 28 1p. Supplement: 5
Subject
Language
English
ISSN
15698041